DataSheet_2_Efficacy and safety of metformin in combination with chemotherapy in cancer patients without diabetes: systematic review and meta-analysis.docx

BackgroundThe results of a meta-analysis of retrospective studies suggest that the use of metformin in cancer patients may prolong progression-free disease survival and overall survival. However, the studies included in the meta-analysis did not strictly distinguish between patients with or without type 2 diabetes mellitus. Therefore, further studies are needed to assess whether the use of adjuvant chemotherapy with metformin in cancer patients without diabetes improves prognosis.MethodSystematic searches of Embase, Pubmed, and The Cochrane library were performed for the subject terms metformin and neoplasm and for free words. Data related to PFS, OS were extracted according to inclusion exclusion criteria. The data were combined and meta-analysis was performed using Review Manager 5.4 to confirm the efficacy and safety of metformin administration.ResultsThere were 3228 publications retrieved from the database and a total of 13 publications with 955 patients were included in the meta-analysis after screening. All included studies were randomised controlled trials. Metformin combined with adjuvant chemotherapy did not improve progression-free survival (HR=1,95CI 0.79-1.25), overall survival (HR=0.91,95% CI 0.69-1.20) and did not improve objective disease response rates in patients. There was no significant difference in grade 3-4 adverse reactions compared to placebo.ConclusionIn this meta-analysis of randomised controlled trial studies, we found that chemotherapy in combination with metformin in cancer patients without diabetes did not prolong progression-free survival and overall survival and improved disease control in patients, although there was no significant difference in terms of safety. More high-quality randomised controlled trials are needed in the future to confirm the in vivo anti-tumour activity and survival benefit of metformin.</p

DataSheet_1_Efficacy and safety of metformin in combination with chemotherapy in cancer patients without diabetes: systematic review and meta-analysis.pdf

BackgroundThe results of a meta-analysis of retrospective studies suggest that the use of metformin in cancer patients may prolong progression-free disease survival and overall survival. However, the studies included in the meta-analysis did not strictly distinguish between patients with or without type 2 diabetes mellitus. Therefore, further studies are needed to assess whether the use of adjuvant chemotherapy with metformin in cancer patients without diabetes improves prognosis.MethodSystematic searches of Embase, Pubmed, and The Cochrane library were performed for the subject terms metformin and neoplasm and for free words. Data related to PFS, OS were extracted according to inclusion exclusion criteria. The data were combined and meta-analysis was performed using Review Manager 5.4 to confirm the efficacy and safety of metformin administration.ResultsThere were 3228 publications retrieved from the database and a total of 13 publications with 955 patients were included in the meta-analysis after screening. All included studies were randomised controlled trials. Metformin combined with adjuvant chemotherapy did not improve progression-free survival (HR=1,95CI 0.79-1.25), overall survival (HR=0.91,95% CI 0.69-1.20) and did not improve objective disease response rates in patients. There was no significant difference in grade 3-4 adverse reactions compared to placebo.ConclusionIn this meta-analysis of randomised controlled trial studies, we found that chemotherapy in combination with metformin in cancer patients without diabetes did not prolong progression-free survival and overall survival and improved disease control in patients, although there was no significant difference in terms of safety. More high-quality randomised controlled trials are needed in the future to confirm the in vivo anti-tumour activity and survival benefit of metformin.</p

Table_1_Efficacy and safety of metformin in combination with chemotherapy in cancer patients without diabetes: systematic review and meta-analysis.xlsx

BackgroundThe results of a meta-analysis of retrospective studies suggest that the use of metformin in cancer patients may prolong progression-free disease survival and overall survival. However, the studies included in the meta-analysis did not strictly distinguish between patients with or without type 2 diabetes mellitus. Therefore, further studies are needed to assess whether the use of adjuvant chemotherapy with metformin in cancer patients without diabetes improves prognosis.MethodSystematic searches of Embase, Pubmed, and The Cochrane library were performed for the subject terms metformin and neoplasm and for free words. Data related to PFS, OS were extracted according to inclusion exclusion criteria. The data were combined and meta-analysis was performed using Review Manager 5.4 to confirm the efficacy and safety of metformin administration.ResultsThere were 3228 publications retrieved from the database and a total of 13 publications with 955 patients were included in the meta-analysis after screening. All included studies were randomised controlled trials. Metformin combined with adjuvant chemotherapy did not improve progression-free survival (HR=1,95CI 0.79-1.25), overall survival (HR=0.91,95% CI 0.69-1.20) and did not improve objective disease response rates in patients. There was no significant difference in grade 3-4 adverse reactions compared to placebo.ConclusionIn this meta-analysis of randomised controlled trial studies, we found that chemotherapy in combination with metformin in cancer patients without diabetes did not prolong progression-free survival and overall survival and improved disease control in patients, although there was no significant difference in terms of safety. More high-quality randomised controlled trials are needed in the future to confirm the in vivo anti-tumour activity and survival benefit of metformin.</p

Two-Step Synthesis of π‑Expanded Maleimides from 3,4-Diphenylfuran-2(5<i>H</i>)‑ones

An efficient two-step synthesis of π-expanded maleimide derivatives was reported, which proceeded via a photoinduced dehydrogenative annulation of 3,4-diphenylfuran-2­(5H)-ones in EtOH at room temperature for 5 h under an argon atmosphere, followed by interaction with primary amine in the presence of 1,8-diazabicyclo[5.4.0]­undec-7-ene and O2. The synthesis of highly conjugated maleimides demonstrated that 3,4-diphenylfuran-2­(5H)-ones were useful precursors for synthesis of π-expanded lactones and π-expanded maleimides with no need of a transition-metal catalyst. Additionally, the fluorescent properties of the highly conjugated maleimides were characterized and were found to possess high fluorescence quantum yields in dichloromethane solution

Synthesis of Polycyclic Heteroaromatic Coumarins via Photoinduced Dehydrogenative Annulation of 4‑Phenyl-3-heteroarylcoumarins

An efficient, oxidant and metal-free synthesis of polycyclic heteroaromatic coumarins was developed. H-Furo­[2′,3′:3,4]­naphtho­[2,1-c]­chromen-4-one (2a–2f), 1H-benzo­furo­[2′,3′:3,4]­naphtho­[2,1-c]­chromen-1-one (2g–2j), and 4H-thieno­[2′,3′:3,4]­naphtho­[2,1-c]­chromen-4-one (2k–2s) derivatives were obtained by the irradiation of 4-phenyl-3-hetero­aryl­coumarin in EtOH–H2O (9:1, v/v) using a high-pressure Hg lamp as the light source, at room temperature and under an Ar atmosphere. Owing to the expansion of the π-conjugation system, 2a–2s showed strong fluorescence emissions in ethanol solution (ΦF = 0.40–0.83)

Additional file 5: of Resequencing of Capsicum annuum parental lines (YCM334 and Taean) for the genetic analysis of bacterial wilt resistance

The list of gene-associated SNPs with type, positions and sequence context. (XLSX 11974 kb

Synthesis of Polycyclic Heteroaromatic Coumarins via Photoinduced Dehydrogenative Annulation of 4‑Phenyl-3-heteroarylcoumarins

An efficient, oxidant and metal-free synthesis of polycyclic heteroaromatic coumarins was developed. H-Furo­[2′,3′:3,4]­naphtho­[2,1-c]­chromen-4-one (2a–2f), 1H-benzo­furo­[2′,3′:3,4]­naphtho­[2,1-c]­chromen-1-one (2g–2j), and 4H-thieno­[2′,3′:3,4]­naphtho­[2,1-c]­chromen-4-one (2k–2s) derivatives were obtained by the irradiation of 4-phenyl-3-hetero­aryl­coumarin in EtOH–H2O (9:1, v/v) using a high-pressure Hg lamp as the light source, at room temperature and under an Ar atmosphere. Owing to the expansion of the π-conjugation system, 2a–2s showed strong fluorescence emissions in ethanol solution (ΦF = 0.40–0.83)

Additional file 7: of Resequencing of Capsicum annuum parental lines (YCM334 and Taean) for the genetic analysis of bacterial wilt resistance

CAPS genotyping results in 156 RIL population from a cross of YCM334 and Taean using selected SNP marker (CA04G03400 SNP1, Additional file 1: Figure S1) and BW resistance phenotype scored from 1 (most resistant) to 5 (most susceptible). (XLSX 13 kb

Additional file 4: of Resequencing of Capsicum annuum parental lines (YCM334 and Taean) for the genetic analysis of bacterial wilt resistance

Indel based CAPS primers. (XLSX 15 kb

Reactive Oxygen Species and Glutathione Dual Redox-Responsive Supramolecular Assemblies with Controllable Release Capability

A dual redox and biorelevant triggered supramolecular system is developed through noncovalent supramolecular inclusion interactions between the ferrocene (Fc) modified on camptothecin (CPT) and β-cyclodextrin (β-CD) at the end of methoxy polyethylene glycol (mPEG). With these two segments, a stable noncovalent supramolecular structure, i.e., mPEG-β-CD/Fc-CPT, can be formed, and then self-assembled into micellar structures in water. Interestingly, these supramolecular micelles showed uniform sphere structure, high and constant drug loading content, hyper-fast redox-responsive drug release, and exhibited equal cellular proliferation inhibition toward A549 cancer cells. The cytotoxicity evaluation of mPEG-β-CD also indicated good biocompatibility. In vivo results revealed the mPEG-β-CD/Fc-CPT nanoparticles had higher in vivo efficacy without side effects. It is anticipated this supramolecular complex may serve as a new kind of promising alternative for drug delivery systems